Senior Director, HEOR/RWE, Lung

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, HEOR/RWE is responsible for developing the strategy and executing HEOR plans and activities related to all Revolution Medicines assets intended for use in non-small cell lung cancer (NSCLC). They will be accountable for demonstrating the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions.

They will work closely with the Medical Affairs team as well as other cross-functional teams to optimize the Integrated Evidence Plan (IEP) and to deliver evidence supporting the use of Revolution Medicines products. The candidate must also be able to provide input and strategic guidance on the global value of the product as well as have demonstrated success in evidence generation globally. The Senior Director HEOR/RWE will participate with the matrix team across the function to ensure alignment of all activities with the strategic and tactical plans.

This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in oncology. Reporting to the Executive Director of HEOR/RWE Lung, the Senior Director, HEOR/RWE : Align with Medical Affairs and Development leadership to design research and deliver evidence consistent with the medical strategy and IEP. Develops and evolves product HEOR/RWE strategy globally, including integration with development, commercial, regulatory, and market access planning.

Deliver HEOR/RWE tactics with quality and in alignment with agreed upon timing. Provide HEOR/RWE leadership on matrix teams and working groups. Work with the HEOR/RWE and Medical Affairs leadership to ensure critical value insights are communicated to key internal teams.

Provide HEOR evidence which addresses the needs and expectations of key stakeholders such as patients, healthcare providers, payers and Health Technology Assessment (HTA) agencies. Leads enterprise partnerships with payers, HTA agencies, and global consortia to help shape access strategy, policies, evidence standards, and evidence generation activities. Effectively present research findings to internal and external stakeholders to improve internal decision making and to promote wider adoption of research findings across external stakeholders.

Facilitate the communication of the value proposition of Revolution Medicines’ portfolio, allowing key healthcare and formulary professionals to make informed therapeutic decisions. Engage and collaborate with external partners including payers, health care providers, thought leaders, patient advocates, and decision-makers to establish/maintain strong partnerships and gather insights into research programs. Facilitate and implement real-world research partnership engagements with leading healthcare, academic and payer organizations to co-create value evidence and help drive evidence-based optimal care.

Stay up to date with and add to the advancements in health economics methodologies and best practices. Identify and interface with HEOR RWE experts and organizations, profile data sources and related organizations as they relate to Revolution Medicines’ portfolio and therapeutic areas.